<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664895</url>
  </required_header>
  <id_info>
    <org_study_id>DELFINO trial</org_study_id>
    <nct_id>NCT03664895</nct_id>
  </id_info>
  <brief_title>Density Lowering Effect of &quot;OFS Add on to TMX&quot;(DELFINO Trial)</brief_title>
  <official_title>Density Lowering Effect of Ovarian Function Suppression in Premenopausal Breast Cancer Patients Who Had no Density Change With One Year of Tamoxifen Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DELFINO tial is designed to investigate the role of &quot;OFS add on to TMX &quot;, based on MMG
      density as a surrogate marker in premenopausal women

        -  Premise - MMG density as a surrogate marker of hormone therapy

        -  Assumption - &quot;Add on OFS to TMX&quot; would have further decrease of density

             -  3-arm(Observation arm + Randomised 2-arm), phase III, RCT with 1:1 allocation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enroll : Sep03,2018~(Planned N= 224)

        1. Inclusion criteria

             -  Premenopausal

             -  ER+

             -  Planned tamoxifen(TMX)

             -  No planned ovary function suppression(OFS)

             -  Regardless of ChemoTx

             -  Mammography(MMG) density check via Volpara*(=Baseline MMG density, BaMD) (*Volpara=
                software to check MMG density)

        2. Check MMG Density via Volpara After 1yr TMX (At1yrMD) Check menopausal status after 1yr
           TMX(Menstruation episode or FSH &lt;30)

        3. MMG Density Reduction(MDR =BaMD-AtMD ) at 1yr

        4. MDR ≥5% -&gt; Keep go on TMX MDR &lt;5% -&gt; 1:1 randomization -&gt; Keep go on TMX vs OFS add on
           to TMX

        5. Analysis : 5yr MDR (1'endpoint), 5yr DFS(2'endpoint), 5yr OS

        6. Calculation of patients' number In previous study(&lt;Kim et al. Breast Can Res 2012&gt;) MDR
           (Mammography Density Reduction) was found in about 50% of all patients who received
           endocrine therapy.

      Expected

        -  MDR in &quot;TMX only&quot; cohort -&gt; 6 ± 7%

        -  MDR in &quot;OFS add on to TMX&quot; -&gt; 10 ± 7%

             -  after 1yr, Significance level 5%, average MDR 4% difference, 80% power, 10% dropout
                rate =&gt; 1:1 randomization Number = 112(56:56) Total number = 224
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">October 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MMG density Reduction</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Breast Cancer Invasive</condition>
  <arm_group>
    <arm_group_label>observation arm(TMX, MDR≥5%)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>keep go on TMX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm(TMX, MDR&lt;5%)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>keep go on TMX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OFS add arm(TMX + OFS, MDR&lt;5%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OFS add on to TMX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuplin or zoladex</intervention_name>
    <description>OFS(Leuplin or zoladex) add on to TMX</description>
    <arm_group_label>OFS add arm(TMX + OFS, MDR&lt;5%)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women, ER+ breast cancer, stage I~III, underwent standard treatment
             including surgery, Planned TMX

          -  available MMG density check via Volpara

        Exclusion Criteria:

          -  Bilateral breast cancer

          -  Prior endocrine therapy

          -  Postmenopausal status

          -  unavailable MMG density check via volpara before and after TMX
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonshik Han</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University College of Medicine/Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eun-Shin Lee</last_name>
    <phone>82-2-2072-0173</phone>
    <email>silvershoe99@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wonshik Han, MD PhD</last_name>
      <phone>82-2-2072-1958</phone>
      <email>hanw@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Eun-Shin Lee, MD</last_name>
      <email>silvershoe99@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eun-Shin Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>September 7, 2018</last_update_submitted>
  <last_update_submitted_qc>September 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>premenopausal women, MMG density, Ovary function suppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

